Chidamide Tablets are a prescription anti-tumor medication primarily indicated for adult patients with specific types of lymphoma and must be used under the guidance of a physician. By regulating epigenetic mechanisms to inhibit tumor cell proliferation, this drug is only prescribed to patients who meet clear clinical indications, with strict adherence to treatment regimens and monitoring requirements mandatory.
Indicated Populations
Adult patients diagnosed with Peripheral T-Cell Lymphoma (PTCL)
The approved indication of chidamide in China is for relapsed or refractory peripheral T-cell lymphoma in patients with a history of at least one prior systemic chemotherapy. Clinically, it may be administered as a monotherapy or in combination with chemotherapy; the specific regimen shall be formulated by the physician based on the patient’s condition.
Patients enrolled in clinical trials for other indications
Chidamide is under research for solid tumors such as breast cancer, and some clinical trials may include patients who meet specific criteria (e.g., hormone receptor-positive advanced breast cancer). Such use must be in accordance with clinical trial protocols, and patients must not attempt self-administration.
Contraindicated and cautionary populations
Contraindicated populations: Patients with hypersensitivity to any component of the drug, as well as pregnant or lactating women (the drug may pose risks to the fetus or infant), are contraindicated from using this medication.
Populations requiring cautious use: Patients with severe hepatic and renal insufficiency, myelosuppression (e.g., low platelet or neutrophil counts), or active infections require a rigorous risk assessment. Physicians may adjust the dosage or temporarily discontinue the medication as needed.
Important Medication Notes
Strictly follow medical advice
The dosage and administration frequency must be in accordance with the physician’s prescription; do not arbitrarily increase/decrease the dosage or discontinue the drug.
Regular monitoring
Routine examinations of blood routine, hepatic and renal function, and electrolytes are required during treatment to promptly detect adverse reactions such as myelosuppression and infection.
Adverse reaction management
Common adverse reactions include fatigue, diarrhea, and thrombocytopenia. Seek immediate medical attention if high fever, bleeding tendency, or severe skin rash occurs.
Medical Consultation Guidelines
Chidamide is a prescription drug, and its use must be determined by an oncologist after a comprehensive assessment of the patient’s condition, prior treatment history, and physical status. Regular follow-ups are necessary during the medication period, and physicians will dynamically adjust the treatment regimen based on therapeutic efficacy and tolerability. Do not purchase the drug or alter the treatment regimen without professional medical guidance.
